15.11.2012 • NewsMerckQ3 2012sales and profits

Merck KGaA Lifts Outlook on Drugs, Screen Chemicals

Merck KGaA lifted its 2012 outlook on Thursday and beat expectations for third-quarter results as it capitalised on its strong position in the market for chemicals for flat screens.

Family-controlled Merck, which traces its roots to a 17th century pharmacy, now expects adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) this year of €2.90-2.95 billion ($3.7-$3.75 billion).

That is the upper half of its previous target range and compares with €2.9 billion expected on average by analysts.

Merck also benefited from continue price increases in the U.S. for multiple sclerosis drugs, where the company sells its established Rebif injection, and from an ongoing cost cutting programme.

Third-quarter adjusted EBITDA rose 15.6% to €754 million, above a forecast for 740 million in a Reuters poll. Revenues also exceeded expectations.

Merck's dominant position in the market for liquid crystals for flat-panel displays allows it to hold its own even as economic uncertainty puts consumers off big-ticket purchases such as pricey flat-screen TVs. Soaring tablet computer sales also help Merck.

The company is slashing costs and jobs after a number of setbacks in drugs development left it without any significant pharmaceuticals in its late-stage development pipeline.

 

 

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.